Abbott To Add Cholesterol Drugs With Kos Deal

  • November 7, 2006
Abbott Laboratories on Monday agreed to pay $3.7 billion for Kos Pharmaceuticals Inc., in a move that will add two major cholesterol drugs to its product lineup. Kos specializes in lipid-management products. It makes Niaspan, which helps raise "good" cholesterol levels, and Advicor, an advanced cholesterol treatment. "In speaking with Abbott, it is our sense that the company is excited to expand its lipid franchise and is optimistic about the prospects for fixed-dose combination therapies," said Banc of America Securities analyst Glenn Novarro.
Next story loading loading..